Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Sec Form 10K
Johnson & Johnson (NYSE: JNJ) Sec Form 10K
Johnson & Johnson (JNJ) Barclays 28th Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) FY 2026 Corporate Conference
ADVERTISEMENT
Johnson & Johnson (JNJ) Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q4 2025 Earnings Call dated Jan. 21, 2026 Corporate Participants: Darren Snellgrove — Vice President of Investor Relations Joaquin Duato…
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q2 2025 Earnings Call dated Jul. 16, 2025 Corporate Participants: Darren Snellgrove — Vice President, Investor Relations Joaquin Duato —…
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q3 2025 Earnings Call dated Oct. 14, 2025 Corporate Participants: Darren Snellgrove — Vice President of Investor Relations Joaquin Duato…
ADVERTISEMENT
AlphaGraphs
Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today. Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was…
Johnson & Johnson: Healthcare Outlook
Earnings Preview Overview Johnson & Johnson approaches earnings as a focused healthcare company following the consumer health separation. Results will...